Dr Mark Agostino
Senior Protein Scientist
Dr Mark Agostino completed a PhD in structure-based drug design at Monash University in 2011. Throughout postdoctoral appointments at Curtin University and the Barcelona Supercomputing Centre, he developed a research program focused on the use of computational approaches to understand the structural basis of molecular interactions relevant to biochemical processes and pharmaceutical design. His research has focused on traditionally challenging targets, such as carbohydrate-protein interactions, DNA-protein interactions, protein-protein interactions, and modulating functionally interesting large-scale conformational changes in proteins. Since 2022, Mark has been a senior consultant with PTNG Scientific, where he applies his diverse technical and biochemical expertise to a wide range of industry-initiated projects, in areas such as small molecule drug discovery, fusion protein design, antibody design, and antibody epitope screening.
